Navigation Links
Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit
Date:10/8/2008

of Arizona Heart Institute and Arizona Heart Hospital. "The myoblast cells are derived from a patient's own skeletal muscle tissue thereby reducing risk of rejection. Further, myoblasts can be delivered to the heart muscle in a minimally invasive fashion via a catheter under local anesthesia. Quite literally, a patient may be able to heal their own heart."

Congestive Heart Failure is a condition in which the heart cannot pump enough oxygen-rich blood to the body's other organs, often as a result of prior heart attack. As blood flow out of the heart slows, blood returning to the heart through the veins backs up, causing congestion in the tissues. Patients with CHF often experience swelling, fatigue and shortness of breath. It affects over five million Americans today.

Patients with CHF have portions of the heart muscle that are severely damaged, usually due to a heart attack. Unlike other tissues in the body, the human heart does not have the ability to repair itself, weakening the heart muscle's ability to function as it did before the heart attack. Without treatment, the heart may grow weaker, eventually resulting in an irreversible situation. Patients with advanced, severe heart failure that do not respond to any treatment method may be considered for heart transplantation. The hope is that Myoblast Therapy may someday replace heart transplantation as the primary option for patients with severe CHF, giving them a new lease on life.

To date, upwards of 235 CHF patients have been treated worldwide using myoblasts. Myoblast transplantation for congestive heart failure is investigational and not approved commercially in the U.S. To be eligible for the MARVEL research study, a patient must be diagnosed with chronic Class II - IV CHF, stable and on optimal medical therapy for at least 60 days, and between the ages of 18-80. To make an appointment at Arizona Heart Institute, or for more information about the MARVEL research study, please call (602)
'/>"/>

SOURCE Arizona Heart Institute
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 BioSpecifics Technologies Corp. (Nasdaq: ... in class collagenase-based products, today announced top-line efficacy ... trial of XIAFLEX(TM) for the treatment of Peyronie,s ... of inelastic collagen on the shaft of the ... sexual intercourse difficult or impossible in advanced cases. ...
(Date:12/16/2009)... -- MAQUET Cardiovascular LLC, a leading provider ... has signed a three-year single source provider ... contracting company, for MAQUET,s market-leading VASOVIEW Endoscopic ... assist healthcare providers in obtaining veins for ... small incisions. This allows for faster healing, ...
(Date:12/16/2009)... -- The Boards of Silence Therapeutics plc (AIM: ... the merger of their businesses to form a ... interference). The enlarged company, to be called ... and delivery technologies, a broad internal and partnered ... property. ,, The Directors believe the merger ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 2Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 5Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 6CuraGen Updates CR011 vcMMAE Data at ASCO 4512 1CuraGen Updates CR011 vcMMAE Data at ASCO 4512 2CuraGen Updates CR011 vcMMAE Data at ASCO 4512 3CuraGen Updates CR011 vcMMAE Data at ASCO 4512 4CuraGen Updates CR011 vcMMAE Data at ASCO 4512 5CuraGen Updates CR011 vcMMAE Data at ASCO 4512 6CuraGen Updates CR011 vcMMAE Data at ASCO 4512 7Abbott 26 BioGenex Extend the Technology Co development and Distribution Agreement for Marketing the Xmatrx 28R 29 Advanced Staining Platform for the 12406 1Abbott 26 BioGenex Extend the Technology Co development and Distribution Agreement for Marketing the Xmatrx 28R 29 Advanced Staining Platform for the 12406 2The Killing of George Tiller 3A Video 26quot 3BThine Eyes 26quot 3B Shows True Face of Pro life Movement in the Face of 26apos 3BTerrorist 26apos 3 47577 1The Killing of George Tiller 3A Video 26quot 3BThine Eyes 26quot 3B Shows True Face of Pro life Movement in the Face of 26apos 3BTerrorist 26apos 3 47577 2
... alfa-2b) dosed every two weeks met the primary ... peginterferon alfa-2a dosed weekly in patients with genotype ... 900-mcg Albuferon had comparable rates of serious and/or ... of global marketing applications planned in fall 2009 ...
... 6 The American Medical Association (AMA) Foundation announced today the 28 ... the program provides $2,500 grants to medical students, physician residents and fellows ... award winners are conducting research in the following four categories: , ... Cardiovascular/pulmonary diseases , HIV/AIDS , ...
Other Medicine Technology:Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 2Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 3Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 4Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 5Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 7Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 8Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 9Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 10AMA Foundation Announces Seed Grant Research Recipients 2AMA Foundation Announces Seed Grant Research Recipients 3
(Date:12/16/2009)... Dec. 16 Shoppers like knowing if ... or Argentina. But grocers have found it burdensome ... (COOL) laws requiring them to provide the information ... at easyCOOLnow.com for easily making grocery ... include provisions that require retailers of unprocessed fruits, ...
(Date:12/16/2009)... MassMutual,s Retirement Services Division has announced plans to ... Q2 2010. The new platform will include a ... materials in a variety of themes. Plan sponsors ... menu of creative options to support the theme ... new RetireSmart participant engagement platform will be phased ...
(Date:12/16/2009)... School of Medicine,s (BUSM) Pulmonary Center has received ... Heart, Lung, and Blood Institute to derive stem ... disease. , Darrell Kotton, MD, associate professor ... PhD, assistant professor of medicine, are the principal ... and Mostoslavsky lead a multicenter investigative team of ...
(Date:12/16/2009)... agency, is honored to announce that Chris Wepfer and Jackie ... Year in Healthcare Traveler magazine’s 2009 Recruiters of the Year ... received such honors and the first for Jackie. , ... ... Solutions, a national healthcare staffing agency, is honored to announce ...
(Date:12/16/2009)... Medizone International, Inc. (OTC Bulletin Board: MZEI) ... the Board of Medizone New Zealand Ltd., a ... a 50% interest, agreed on December 14, 2009 ... Medizone International all global marketing rights of the ... G. Marshall said, "Time has eroded the relevance ...
Breaking Medicine News(10 mins):Health News:New Website Helps Grocers Comply With COOL Laws 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 3Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2
... Calif., May 12 Medical Care Corporation (MCC), ... technology, announced today that physicians now have a ... Screen, which enables them to accurately separate normal ... of memory loss associated with an underlying medical ...
... Call to Action demonstrates commitment to combating a leading ... and WaterAid America released two new reports today that ... are not responding to clear evidence on child mortality ... Diarrheal disease, a leading killer of children under age ...
... the skin , , TUESDAY, May 12 (HealthDay News) -- Any ... eased chronic lower back pain in a group of adult ... Cherkin, lead author of a report published in the May ... "Acupuncture is an effective treatment for chronic back pain. People ...
... Week 2009 -CAMBRIDGE, Mass. and NEW YORK, May 12, ... (NYSE: FRX ) today announced they will ... studies for linaclotide, a first-in-class investigational compound for the ... chronic constipation (CC), during the 2009 Digestive Disease Week ...
... 12 Last month The National Alliance of Advocates for ... patients seeking treatment for painkiller or heroin addiction compared to ... track for an astounding 200% gain. Dr. Michael Stein, author ... Oprah Magazine and The New York Times , tells ...
... MOUNTAIN VIEW, Calif., May 12 Based on ... market, Frost & Sullivan recognizes Sypris Test & ... & Sullivan Customer Service Leadership Award. This ... constant innovations, and strategic partnerships that have given ...
Other Medicine News:Health News:Medical Care Corporation Enables Early Detection of Memory Loss Due to Alzheimer's Disease 2Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 2Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 3Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 4Health News:Acupuncture, Real or Fake, Eases Back Pain 2Health News:Acupuncture, Real or Fake, Eases Back Pain 3Health News:Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide 2Health News:Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide 3Health News:Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide 4Health News:Economy Impacts People Seeking Treatment for Addiction - 80% Increase Over Last Year 2Health News:Economy Impacts People Seeking Treatment for Addiction - 80% Increase Over Last Year 3Health News:Frost & Sullivan Acknowledges Sypris for High-Quality Calibration Solutions 2Health News:Frost & Sullivan Acknowledges Sypris for High-Quality Calibration Solutions 3Health News:Frost & Sullivan Acknowledges Sypris for High-Quality Calibration Solutions 4
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
Clip-On Glasses clip onto regular eyewear frames. Plano (nonprescription) only. Will not fit over high-plus or high-minus presciptions, or over glasses with thick frames. Black wire frames. Wt. 63 g....
Portable shields for your safety and convenience....
Medicine Products: